预约演示

更新于：2025-05-07

CCL23

更新于：2025-05-07

基本信息

别名

C-C motif chemokine 23、C-C motif chemokine ligand 23、CCL23

+ [15]

简介

Shows chemotactic activity for monocytes, resting T-lymphocytes, and neutrophils, but not for activated lymphocytes. Inhibits proliferation of myeloid progenitor cells in colony formation assays. This protein can bind heparin. Binds CCR1. CCL23(19-99), CCL23(22-99), CCL23(27-99), CCL23(30-99) are more potent chemoattractants than CCL23.

关联

项与 CCL23 相关的药物

HG-1089

靶点

CCL23

作用机制

CCL23 modulators

在研机构-

原研机构

Human Genome Sciences, Inc.

在研适应症-

非在研适应症

免疫系统疾病 [+2]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 CCL23 相关的临床结果

登录后查看更多信息

100 项与 CCL23 相关的转化医学

登录后查看更多信息

0 项与 CCL23 相关的专利（医药）

登录后查看更多信息

477

项与 CCL23 相关的文献（医药）

2025-12-01·Clinical Proteomics

ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink® proteomics approach

Article

作者: Jhan, Pei-Pei ; Hung, Miao-Neng ; Tsai, Jia-Rung ; Hsiao, Tzu-Hung ; Chen, Chung-Hsing ; Li, Hsin-Ni ; Wu, Ting-Shuan ; Teng, Chieh-Lin Jerry

BACKGROUNDThe standard "7 + 3" induction results in 30% of de novo acute myeloid leukemia (AML) patients not achieving complete remission (CR). We aimed to utilize the Olink^® platform to compare the bone marrow plasma proteomic profiles of newly diagnosed de novo AML patients who did and did not achieve CR following "7 + 3" induction treatment.METHODSThis prospective study included 43 untreated AML patients, stratified into CR (n = 29) and non-CR (n = 14) groups based on their response to "7 + 3" induction therapy. We employed the Olink^® Explore-384 Inflammation platform for proteomic analysis to investigate differences in bone marrow plasma protein levels between the CR and non-CR groups.RESULTSProteomic analysis demonstrated that the CR group exhibited significantly higher bone marrow plasma levels of ARTN and CCL23 than did the non-CR group. Immunohistochemical staining confirmed a higher proportion of tissue samples with intense staining for ARTN (25.40% vs. 7.05%, p = 0.013) and CCL23 (24.14% vs. 14.29%, p = 0.039) in the CR group. These findings were corroborated by bulk-RNA-seq, which indicated significantly elevated mRNA expression levels of ARTN (1.93 vs. -0.09; p = 0.003) and CCL23 (1.50 vs. 0.12; p = 0.021) in the CR group. The Human Protein Atlas provided external support for our findings.CONCLUSIONSThe results suggest that ARTN and CCL23 may serve as biomarkers for predicting responsiveness to the "7 + 3" induction in untreated AML. Using an enzyme-linked immunosorbent assay to identify the roles of ARTN and CCL23 in predicting AML chemosensitivity may enhance clinical applicability in the future.

2025-12-01·Inflammation Research

Exploring druggable targets and inflammation-mediated pathways in cancer: a Mendelian randomization analysis integrating transcriptomic and proteomic data

Article

作者: Jing, Changqing ; Pan, Hao

BACKGROUNDCancer remains a predominant global health challenge, necessitating the ongoing exploration of novel biomarkers and therapeutic targets to improve diagnosis and treatment.METHODSBy integrating expression quantitative trait loci (eQTL) and protein quantitative trait loci (pQTL) data with genome-wide association studies (GWAS) data, we performed Mendelian randomization (MR) analysis to identify potential druggable targets at the gene expression and protein levels for multiple cancers. We conducted mediation analysis to explore whether inflammatory factors mediate the pathways linking identified druggable targets to cancer. Phenome-wide MR analysis, drug prediction, and molecular docking were employed to evaluate the medicinal potential.RESULTSWe finally identified five druggable targets: CDKN1A, FES, and PDIA3 were associated with breast cancer, whereas TP53 and VAMP8 were associated with prostate cancer. Mediation analysis identified six inflammatory proteins as potential mediators in the causal pathways from these druggable targets to cancer: caspase 8, interleukin-1-alpha, C-X-C motif chemokine 1, C-C motif chemokine 23, TNF-related apoptosis-inducing ligand, and interleukin-6. Subsequent analyses further provided evidence supporting the pharmaceutical potential of these five targets.CONCLUSIONSOur study identified five druggable targets causally associated with breast and prostate cancers, with six inflammatory proteins acting as potential mediators, providing novel insights into the treatment of these cancers.

2025-04-15·The Journal of Infectious Diseases

Nasal Mucosal Cytokines as Potential Biomarkers for Assessing Disease Severity and Class of Pathogen in Children With Community-Acquired Pneumonia

Article

作者: Sayegh, Rouba ; Everhart, Kathy ; El-Assal, Osama ; Cohen, Daniel M ; Keaton, Meghan ; Desai, Ankita ; Xu, Zhaohui ; Marzec, Sarah A ; Florin, Todd A ; Tang, Li ; Shah, Samir S ; Mertz, Sara ; Alter, Sherman J ; Wallihan, Rebecca ; Mejias, Asuncion ; Yun, Ki Wook ; Leber, Amy L ; Ramilo, Octavio ; Ruddy, Richard M ; Ambroggio, Lilliam

AbstractBackgroundCommunity-acquired pneumonia (CAP) is a leading cause of morbidity and mortality in children. Assessing disease severity and etiology remains challenging in the clinical setting. The objective of this study was to identify mucosal biomarkers that could potentially assist with patient classification.MethodsWe analyzed mucosal concentrations of cytokines in nasopharyngeal samples obtained from a convenience sample of 182 children with CAP and 26 matched healthy controls. Pathogens were identified by cultures and molecular assays. Severe disease was defined by hospital stay ≥3 days and/or pediatric intensive care unit admission. Data were analyzed according to identified pathogens and disease severity.ResultsChildren with CAP and detected atypical bacteria had significantly higher concentrations of monocyte chemotactic protein 2 (MCP-2), interferon gamma (IFN-γ), and CXCL10, among others, compared with those with typical bacteria. Children with influenza virus had significantly higher concentrations of MCP-2, CXCL10, CXCL11, CX3CL1, and IFN-γ than those with typical bacteria. Additionally, children with severe CAP had significantly higher concentrations of CCL23 than children with mild/moderate disease, irrespective of the pathogen(s) identified.ConclusionsWe identified differences in mucosal concentrations of inflammatory and antiviral cytokines in children with CAP according to disease severity and detected pathogens. Mucosal biomarkers represent a promising approach to help assess disease severity and etiology.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。